Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
January 17, 2024 07:15 ET
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
January 08, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation...
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023 07:00 ET
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
December 13, 2023 09:15 ET
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
November 09, 2023 16:15 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Present at the 8th Annual Dawson James Conference
October 05, 2023 07:00 ET
|
CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
September 19, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
September 11, 2023 11:32 ET
|
CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
September 01, 2023 16:43 ET
|
CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
August 31, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...